De Novo Sequencing and Resurrection of a Human Astrovirus-Neutralizing Antibody
peer-reviewed · ACS Infectious Diseases · 2016
| Date | 2016-05-13 |
| Type | peer-reviewed |
| Venue | ACS Infectious Diseases |
| Publisher | American Chemical Society (ACS) |
| Contribution | downstream-application |
| DOI | 10.1021/acsinfecdis.6b00026 |
| Citations (OpenAlex) | 16 |
Abstract
Monoclonal antibody (mAb) therapeutics targeting cancer, autoimmune diseases, inflammatory diseases, and infectious diseases are growing exponentially. Although numerous panels of mAbs targeting infectious disease agents have been developed, their progression into clinically useful mAbs is often hindered by the lack of sequence information and/or loss of hybridoma cells that produce them. Here we combine the power of crystallography and mass spectrometry to determine the amino acid sequence and glycosylation modification of the Fab fragment of a potent human astrovirus-neutralizing mAb. We used this information to engineer a recombinant antibody single-chain variable fragment that has the same specificity as the parent monoclonal antibody to bind to the astrovirus capsid protein. This antibody can now potentially be developed as a therapeutic and diagnostic agent.
Methods and tools
- Astrovirus-neutralizing antibody resurrection: Sequences a human astrovirus-neutralizing monoclonal antibody de novo and re-expresses it, addressing the common case where a useful antibody exists as protein but its sequence and cell line do not.
Cites (1)
Cited by (6)
- PepGo: a deep learning and tree search-based model for de novo peptide sequencing (2025) both
- Template-Assisted De Novo Sequencing of SARS-CoV-2 and Influenza Monoclonal Antibodies by Mass Spectrometry (2022) crossref
- pNovo 3: precise de novo peptide sequencing using a learning-to-rank framework (2019) both
- A potential golden age to come—current tools, recent use cases, and future avenues for de novo sequencing in proteomics (2018) crossref
- Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery (2017) both
- Evaluating de novo sequencing in proteomics: already an accurate alternative to database-driven peptide identification? (2017) crossref